Gene

ERBB3

erb-b2 receptor tyrosine kinase 3

Explore in graph →CI-GENE-00044906HGNC:3431 ENSG00000065361 NCBI 2065 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (32)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–32 of 32 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 Mutation + ERBB3 MutationERBB3 ERBB21
Pertuzumab + TrastuzumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER

Cohorts

Alteration frequency by cohort (154)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved154 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Adrenocortical Carcinoma TCGA-ACC	Adrenal Cortical CarcinomaALIAS

Literature

Linked publications (8)

25 per page, newest first.

pubmedPublishedShowing 1–8 of 8 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
· Clin Cancer Res · 2015 · PMID 25520391 · validated civic_curation pubmed
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.
· J Clin Oncol · 2016 · PMID 27044931 · validated civic_curation pubmed
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
· Clin Cancer Res · 2016 · PMID 26920887 · validated civic_curation pubmed
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
· JCO Precis Oncol · 2022 · PMID 36315917

ERBB3 A232V3
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	2	submitted	EID9629 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the A232V mutation in the presence of ERBB2 resulted in modest increases in anchorage inde… (full text at CIViC) PMID 23680147 · Jaiswal et al., 2013 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	2	submitted	EID9631 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the A232V mutation in the presence of ERBB2 resulted in modest increases in anchorage inde… (full text at CIViC) PMID 23680147 · Jaiswal et al., 2013 · Open in CIViC	civic
Duligotuzumab + Lapatinib + Pertuzumab + TrastuzumabSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID9630 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the A232V mutation in the presence of ERBB2 resulted in modest increases in anchorage inde… (full text at CIViC) PMID 23680147 · Jaiswal et al., 2013 · Open in CIViC	civic

ERBB3 A232V3

(functional)

—UNRESOLVED

Functional

Supports Gain Of Function

submitted

EID9629

Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the A232V mutation in the presence of ERBB2 resulted in modest increases in anchorage inde… (full text at CIViC)

PMID 23680147 · Jaiswal et al., 2013 · Open in CIViC

ERBB3 EXPRESSION3
Anti-ErbB3 Monoclonal Antibody AV-203	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID862 The authors conducted an in vivo efficacy study of AV-203 (ERBB3 inhibitory antibody) using a panel of 32 xenograft models representing 12 human cancer types. To identify biomarkers that can predict r… (full text at CIViC) PMID 25542901 · Meetze et al., 2015 · Open in CIViC	civic
Pertuzumab	Melanoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID3051 A preclinical study demonstrating that in a subgroup of BRAF/NRAS wildtype/wildtype showing high levels of phospho-ErbB3, knockdown of NRG1 reduced viability and decreased activation of ErbB3, ErbB2 a… (full text at CIViC) PMID 26206558 · Capparelli et al., 2015 · Open in CIViC	civic
9F7-F11 + PertuzumabCombination	Pancreatic Ductal Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID865 In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agen… (full text at CIViC) PMID 25216528 · Thomas et al., 2014 · Open in CIViC	civic

ERBB3 Overexpression8
Afatinib + SelumetinibCombination	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1152 Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen using a total of 3,530 shRNAs to target 518 human kinases identified ERBB3 knockdown to confer sensitivity of s… (full text at CIViC) PMID 24685132 · Sun et al., 2014 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	4	accepted	EID729 High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were availa… (full text at CIViC) PMID 25520391 · Cushman et al., 2015 · Open in CIViC	civic
Gefitinib + HER2 Inhibitor CP-724,714 + SelumetinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID1153 Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen identified ERBB3 blockade to confer sensitivity to MEK inhibitors. The dual EGFR-ERBB2 (both forming heterodime… (full text at CIViC) PMID 24685132 · Sun et al., 2014 · Open in CIViC	civic
Lapatinib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	3	submitted	EID3053 Women with primary breast cancer were randomized (3:1) to 10 to 14 days of preoperative lapatinib or placebo in a multicenter phase II trial. Biopsies pre-/posttreatment were analyzed for Ki67, apopto… (full text at CIViC) PMID 25398453 · Leary et al., 2015 · Open in CIViC	civic
Patritumab Deruxtecan	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	4	rejected	EID7427 In a phase 1/2 trial, HER3 positive (IHC 2+/3+) advanced breast cancer were treated wtih HER3 targeting antibody-drug conjugate U3-1402. A total of 34 patients positive breast cancer, 3 were HER2 posi… (full text at CIViC) Open in CIViC	civic
Pertuzumab	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID7804 Two lung cancer cell lines, 11_18 and Ma-24, were found to have significantly increased growth when treated with heregulin (HRG)‐α compared to other growth factors. Pertuzumab was found to significan… (full text at CIViC) PMID 17627612 · Sakai et al., 2007 · Open in CIViC	civic
Selumetinib + TrametinibSubstitutes	Uveal Melanoma	Predictive	D	Supports Resistance	4	submitted	EID3050 MEK inhibitors improve survival in cutaneous melanoma patients but show only modest efficacy in metastatic uveal melanoma patients. In this study, we screened for growth factors that elicited resistan… (full text at CIViC) PMID 25952648 · Cheng et al., 2015 · Open in CIViC	civic
Trastuzumab Emtansine	HER2-Positive Breast CarcinomaALIAS	Predictive	B	Does Not Support Resistance	2	accepted	EID8707 In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored higher than median levels of ERBB3 mRNA treated with ado-trastuzumab emtansine (T-DM1… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC	civic